Drug Interactions With Risk of QT-prolongation in a General Hospital

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Katholieke Universiteit Leuven; KU Leuven
• Collaborator: Agentschap voor Innovatie door Wetenschap en Technologie
• Treatments: Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• treatment with haloperidol (started in the hospital)

Exclusion Criteria:

• age < 18 years